Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial

BACKGROUND: The chronic and progressive nature of chronic obstructive pulmonary disease (COPD) requires self-administration of inhaled medication. Dry powder inhalers (DPIs) are increasingly being used for inhalation therapy in COPD. Important considerations when selecting DPIs include inhalation ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Altman, Pablo, Wehbe, Luis, Dederichs, Juergen, Guerin, Tadhg, Ament, Brian, Moronta, Miguel Cardenas, Pino, Andrea Valeria, Goyal, Pankaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001060/
https://www.ncbi.nlm.nih.gov/pubmed/29898702
http://dx.doi.org/10.1186/s12890-018-0662-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001060/
https://www.ncbi.nlm.nih.gov/pubmed/29898702
http://dx.doi.org/10.1186/s12890-018-0662-0

Ejemplares similares